Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 1/2 1

Status

Recruiting 2Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Leukemia, Myeloid, Acute 1Leukemia, Biphenotypic, Acute 1Leukemia 1BRAF V600E Mutation 1

Interventions

Specimen Handling 480pembrolizumab 455Magnetic Resonance Spectroscopy 420Carboplatin 327Cyclophosphamide 314Cisplatin 271Biopsy 271Radiotherapy 244Paclitaxel 229Gemcitabine 227Bevacizumab 213Nivolumab 188fludarabine 185venetoclax 174Drug Therapy 170Blood Specimen Collection 158Dexamethasone 157Oxaliplatin 154Injections 152Capecitabine 151Fluorouracil 144Docetaxel 144Radiosurgery 137Standard of Care 135Rituximab 125Pemetrexed 117durvalumab 115Leucovorin 109atezolizumab 107Radiation 106

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × Cobicistat × 1 year × Clear all
NCT04065399 2026-03-18

AUGMENT-101

Syndax Pharmaceuticals

Phase 1/2 Recruiting
447 enrolled 2 FDA
LymphoidOther hematologic neoplasm

Leukemia, Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT06610682 2025-12-10

Feasibility of CSF and Plasma ctDNA in BRAF-altered Glioma During Treatment With Plixorafenib

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase EARLY_PHASE1 Recruiting
15 enrolled

BRAF V600E Mutation

Data powered by HemOnc (CC BY 4.0) Colophon âš¡